Cardiff Oncology Reports Mixed Results as Onvansertib Trials Progress

Introduction

Cardiff Oncology Inc (ticker: CRDF) is a clinical-stage biotechnology company headquartered in San Diego, California. Founded in 1999, the company focuses on leveraging PLK1 inhibition to develop cancer therapies. Its lead asset, onvansertib, is a PLK1 inhibitor being evaluated in combination with standard-of-care agents across multiple oncology indications.

Corporate Structure

Cardiff Oncology is listed on the NASDAQ Global Market under the symbol CRDF. As of mid-2025, the company employs between 11 and 50 staff members, encompassing research, clinical development, regulatory affairs, and corporate functions. Key members of the leadership team include:

• Mark Erlander, PhD, Chief Executive Officer since May 2020, with over 30 years in oncology drug discovery and diagnostics.
• James Levine, Chief Financial Officer since 2021, who previously led financial collaborations valued at over $1.3 billion at Cidara Therapeutics.
• Roger Sidhu, MD, Chief Medical Officer, has experience in advancing multiple therapeutic candidates from Phase 1 through global approvals.
• Tod Smeal, PhD, Chief Scientific Officer since January 2022, with over 20 years in targeted therapy research and several FDA-approved drugs to his credit.

Oncology by Ben Hershey

Recent Developments and News

On July 29, 2025, Cardiff Oncology announced data from CRDF-004, its randomized Phase 2 trial evaluating onvansertib plus standard-of-care in first-line RAS-mutated metastatic colorectal cancer (mCRC). The announcement detailed response rates and safety profiles compared with historical controls. In May 2025, the company reported findings from an investigator-initiated Phase 1b study of onvansertib with paclitaxel in metastatic triple-negative breast cancer, which were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. During the first half of 2025, the U.S. Patent and Trademark Office granted Cardiff a second method-of-use patent covering onvansertib in combination with bevacizumab for bevacizumab-naïve metastatic colorectal cancer across all lines of therapy. The company also completed patient enrollment in the CRDF-004 trial prior to its July data release.

Financial and Strategic Aspects

On May 8, 2025, Cardiff Oncology released financial results for the quarter ended March 31, 2025, indicating its commitment to advance regulatory discussions with the U.S. Food and Drug Administration for onvansertib in RAS-mutated mCRC. As of July 30, 2025, shares of CRDF closed at $2.415, down 27.04% on the day, with trading volume of 2,077,169 shares. The company remains pre-revenue and continues to fund operations through public equity and potential partnership agreements. Its strategy includes advancing onvansertib through clinical readouts and expanding intellectual property protections.

Market Position and Industry Context

Cardiff Oncology operates within the clinical-stage oncology sector, focusing on the development of targeted therapies. Onvansertib addresses PLK1, a cancer target, and is being tested for RAS-mutated mCRC, metastatic pancreatic ductal adenocarcinoma, triple-negative breast cancer, and small cell lung cancer. The company competes with both small biotech firms and larger pharmaceutical companies pursuing RAS biology and combination regimens. Key milestones for Cardiff will include readouts from ongoing trials, regulatory filings for advanced indications, and potential partnering or licensing agreements to support late-stage development and commercialization.

tl;dr

On July 29, 2025, Cardiff Oncology reported data for its onvansertib plus standard-of-care regimen in first-line RAS-mutated mCRC. Shares fell 27.04% on July 30, 2025, closing at $2.415 with 2.08 million shares traded. The company has secured a second method-of-use patent for onvansertib plus bevacizumab and completed enrollment in its Phase 2 trial. Future focus points include FDA discussions for onvansertib in mCRC and additional clinical readouts across multiple tumor types.